002581 Shandong Sinobioway Biomedicine
- 11.41
- +0.07+0.62%
Shandong Sinobioway Biomedicine News
Unnamed Pharmaceutical (002581.SZ) withdraws from Qianhai Weiming M&A Fund
Unnamed Pharmaceutical (002581.SZ) issued an announcement, and the company held the 5th term of directors on May 30, 2024...
Unnamed Pharmaceutical (002581.SZ) received a dividend of 215 million yuan from the participating company Beijing Kexing
Unnamed Pharmaceutical (002581.SZ) announced that the company received a shareholding company, Beijing Kexing Biological Products Co., Ltd. (abbreviation...
Shareholders Have Faith in Loss-making Shandong Sinobioway Biomedicine (SZSE:002581) as Stock Climbs 10% in Past Week, Taking Five-year Gain to 83%
Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying the right stocks can give your wealth a significant boost. For example, long ter
Unnamed Pharmaceutical (002581.SZ): Net loss of 27.704 million yuan in the first quarter
On April 30, Ge Longhui Pharmaceutical (002581.SZ) released its report for the first quarter of 2024, achieving operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net profit attributable to shareholders of listed companies - 27.704 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 28.33 million yuan, and basic earnings per share - 0.042 yuan.
Unnamed Pharmaceutical (002581.SZ) reported first-quarter results with a net loss of 27.7041 million yuan
According to Zhitong Finance App, Unnamed Pharmaceutical (002581.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net loss attributable to shareholders of listed companies was 27.7041 million yuan; net loss attributable to shareholders of listed companies deducted 28.33 million yuan for non-recurring profit and loss; basic loss per share was 0.0420 yuan/share.
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up rece
Unnamed Pharmaceuticals (002581.SZ): Shareholder Gao Baolin and his co-actors have not reduced their holdings at the end of the reduction period
Gelonghui, March 4 | Unnamed Pharmaceutical (002581.SZ) announced that the company recently received a “Notice Letter on the Expiration of the Share Reduction Period” issued by shareholder Mr. Gao Baolin and his co-actor Mr. Wang Mingxian. As of the announcement date, the period of this holdings reduction plan had expired, and the company's shareholder Mr. Gao Baolin and his co-actor, Mr. Wang Mingxian, had not reduced their holdings in the company.
Unnamed Pharmaceutical (002581.SZ): Received 53.82 million yuan in dividends from participating companies
Gelonghui, Feb. 5 | Weiming Pharmaceutical (002581.SZ) announced that recently, Shandong Weiming Biomedical Co., Ltd. received a dividend of RMB 53.82 million from the participating company Beijing Kexing Biological Products Co., Ltd. (“Beijing Kexing”).
While Shareholders of Shandong Sinobioway Biomedicine (SZSE:002581) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) shareholders might understandably be very concerned that the share price has dropped 40% in the last quarter. On the bright side the returns
Unnamed Pharmaceutical (002581.SZ): Expected net loss of 240 million yuan to 345 million yuan in 2023
On January 30, Gelonghui Pharmaceutical (002581.SZ) announced that it expects a net loss of 243.39 million yuan to 345.09 million yuan in 2023, after deducting non-net loss of 228.87 million yuan to 330.57 million yuan. According to corporate accounting standards and relevant accounting policy regulations, some long-term assets of the company were tested for impairment based on comprehensive influencing factors such as the company's actual operating conditions, changes in the industry market, and asset operation. The initial judgment was that there may be signs of impairment. According to the company's preliminary estimates, the company is expected to calculate impairment provisions for relevant long-term assets in the 2023 annual report: reduction in fixed assets
Investor Optimism Abounds Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) But Growth Is Lacking
When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.7x, Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) looks
Unknown Pharmaceutical (002581.SZ): Tianjin's unfamous interferon α2b spray plans to win the bid collection project
Unnamed Pharmaceutical (002581.SZ) issued an announcement. Recently, Tianjin Weiming Biomedical Co., Ltd., a holding subsidiary of the company...
Sinobioway Biomedicine's Unit to Relocate
Shandong Sinobioway Biomedicine's (SHE:002581) unit, Peking University Weiming (Hefei) Biopharmaceutical, suspended operations as part of relocation plans. The pharmaceutical company will be relocated
Unnamed Pharmaceutical (002581.SZ), a wholly-owned subsidiary of Unnamed Pharmaceutical (002581.SZ), ceased production in Hefei and relocated
Unnamed Pharmaceutical (002581.SZ) announced that Peking University Weiming (Hefei) Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Health Check: How Prudently Does Shandong Sinobioway Biomedicine (SZSE:002581) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Even Though Shandong Sinobioway Biomedicine (SZSE:002581) Has Lost CN¥818m Market Cap in Last 7 Days, Shareholders Are Still up 129% Over 5 Years
While Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 12% in the la
[Instant Analysis of BT Financial Report] Unnamed Pharmaceutical's 2023 Interim Report: Operating Revenue Increased by 11.47%, Net Profit Loss Expanded, and Cash Flow Pressure Revealed
The 2023 interim report of Unnamed Pharmaceutical (stock code: 002581) has been announced. In the reporting period, the revenue of Unnamed Pharmaceutical was 209,166,285.01 yuan, an increase of 11.47% compared to 187,644,945.23 yuan in the same period last year. However, net profit attributable to shareholders of listed companies during the reporting period was -53,757,277.48 yuan, a decrease of 324.39% compared to 23,956,571.47 yuan in the same period last year. At the same time, net profit attributable to shareholders of listed companies during the reporting period after deducting non-recurring profit and loss was -48,1
Unnamed Medicine (002581.SZ): Received 5 million yuan in government incentives
Gelonghui, September 1: Unnamed Pharmaceutical (002581.SZ) announced that according to the “Notice of the Xiamen Municipal People's Government on Certain Measures to Accelerate the High-Quality Development of the Biomedical Industry” (Xiamen Regulation (2020) No. 7), Unnamed Biomedical Co., Ltd. (“Xiamen Weiming”), a wholly-owned subsidiary of Shandong Weiming Biomedical Co., Ltd. (“Xiamen Weiming”), received a total of RMB 5 million in government incentives related to revenue on August 30, 2023, accounting for 34.04% of the company's most recent audited net profit attributable to shareholders of listed companies.
Sinobioway Biomedicine Taps Builders for Planned Industrial Park
Shandong Sinobioway Biomedicine (SHE:002581) tapped Shandong Qiying Industry Investment Development and Shandong Jutai Industry Development to construct its planned industrial park in Zhangdian Econom
Unknown Pharmaceuticals (002581.SZ): Advance loss of 47.649 million yuan in the first half of the year, year-on-year profit and loss
On July 14, 丨Unknown Pharmaceuticals (002581.SZ) announced its 2023 semi-annual results forecast. Net profit and loss attributable to shareholders of listed companies during the reporting period was 476.49 million yuan, a year-on-year profit to loss; net profit loss of 42.0339 million yuan after deducting non-recurring profit and loss; and a basic loss of 0.0722 yuan/share in earnings per share. The reason for the decline in the company's performance during the reporting period was a decrease in the company's investment income.
Analysis
Price Target
No Data
